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Abstract
Global gray matter (GM) atrophy rates were quantified from magnetic resonance imaging (MRI) over 6- and 12-month intervals in 37
patients with Alzheimer’s disease (AD) and 19 controls using: (1) nonlinear registration and integration of Jacobian values, and (2)
segmentation and subtraction of serial GM volumes. Sample sizes required to power treatment trials using global GM atrophy rate as an
outcome measure were estimated and compared between the 2 techniques, and to global brain atrophy measures quantified using the
boundary shift integral (brain boundary shift integral; BBSI) and structural image evaluation, using normalization, of atrophy (SIENA).
Increased GM atrophy rates (approximately 2% per year) were observed in patients compared with controls. Although mean atrophy rates
provided by Jacobian integration were smaller than those from segmentation and subtraction of GM volumes, measurement variance was
reduced. The number of patients required per treatment arm to detect a 20% reduction in GM atrophy rate over a 12-month follow-up (90%
power) was 202 (95% confidence interval [CI], 118–423) using Jacobian integration and 2047 (95% CI 271 to  10 000) using
egmentation and subtraction. Comparable sample sizes for whole brain atrophy were 240 (95% CI, 142–469) using the BBSI and 196 (95%
I, 110–425) using SIENA. Jacobian integration could be useful for measuring GM atrophy rate in Alzheimer’s disease as a marker of
isease progression and treatment efficacy.
2012 Elsevier Inc.
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Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by progressive cognitive decline. With poten-
tial disease-modifying therapies for AD being developed,
sensitive, objective, and reliable markers of disease progres-
sion and therapeutic effects are crucial. Measurements of
whole brain and hippocampal atrophy rates from serial
structural magnetic resonance imaging (MRI) are potential
markers of the underlying neuroaxonal damage and disease
progression in AD (Fox et al., 2005; Henneman et al., 2009;
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10.1016/j.neurobiolaging.2010.11.001
Open access under CC BY license.Morra et al., 2009; Sluimer, et al., 2008; Whitwell, et al.,
2008).
Gray matter (GM) may lose volume earlier in AD than
white matter (WM) (Serra, et al., 2010; Tanabe et al., 1997),
and GM loss has been shown to be associated with ongoing
pathological and clinical progression of the disease (Whit-
ell et al., 2008; de Jong et al., 2008; Mouton et al., 1998;
erra et al., 2010), and may therefore be a more sensitive
arker of AD pathology than whole brain atrophy.
Despite these observations few studies have specifically
nvestigated rates of global GM atrophy in AD, which may
e a useful marker of disease progression in clinical trials.
ptimizing the power of outcome measures for clinical
rials is important, as the number of subjects required to
how a therapeutic effect on progression may be reduced,
hereby leading to more efficient trials and exposing fewer
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quantifying GM atrophy is segmentation and subtraction of
serial GM volumes (Calabrese et al., 2009; Cardenas et al.,
2003; Moore et al., 2009). However nonlinear registration
of magnetic resonance (MR) images, which determines a
deformation field to match serial scans, could be used to
quantify directly an individual’s gray matter (GM) struc-
tural changes over time (Freeborough and Fox, 1998; Hua et
al., 2009), and provide a measure that is more precise and
which would therefore have greater power to detect change
— largely because the influence of segmentation errors at
each time point is reduced (Anderson et al., 2007a, 2007b).
The aim of this study was to determine global GM atrophy
rates in patients with AD and controls over periods of 6- and
12-months, using: (1) nonlinear registration and Jacobian
integration, and (2) segmentation and subtraction of serial
GM volumes, and to estimate the statistical power of these
2 techniques in potential clinical trials using global GM
atrophy rate as an outcome measure. For comparison, whole
brain atrophy rates were also calculated using 2 registration-
based methods (the brain boundary shift integral; BBSI)
(Fox and Freeborough, 1997; Freeborough and Fox, 1997)
and structural image evaluation, using normalization, of
atrophy (SIENA) (Smith et al., 2002).
2. Methods
Thirty-seven patients with probable AD, recruited from
the Cognitive Disorders Clinic at the National Hospital for
Neurology and Neurosurgery, and 19 control subjects were
included in the study. This cohort has been the subject of a
previous report where full details of inclusion criteria and
clinical assessment have been given (Schott et al., 2005).
One individual recruited to the original study has since had
a postmortem diagnosis of Lewy body dementia, and was
therefore excluded from the current study. Three other pa-
tients have had postmortem confirmation of a diagnosis of
AD. The study was granted ethical approval by the National
Hospital for Neurology and Neurosurgery and Institute of
Neurology joint Research Ethics Committee, and subjects
gave written informed consent.
2.1. MRI scan acquisition
All subjects underwent MRI scanning on a 1.5 T Signa
scanner (GE Medical Systems, Milwaukee, WI, USA) at
baseline and at approximately 6 months and 12 months
(mean intervals 180 days, SD 7; and 365 days, SD 14).
T1-weighted volumetric images were obtained using an
inversion recovery prepared fast spoiled gradient echo se-
quence with acquisition parameters time to repetition  15
ms, time to echo  5.4 ms, flip angle  15°, TI  650 ms,
a 24-cm field of view and a 256  256 matrix, to provide
124 contiguous 1.5-mm thick slices in the coronal plane
(voxels 0.9735 mm  0.9735 mm  1.5 mm). e2.2. MRI scan processing
Images were corrected for intensity inhomogeneity using
the N3 algorithm (www.bic.mni.mcgill.ca/software/N3/)
(Sled et al., 1998), and the images were segmented into
brain/nonbrain using a semiautomated technique (MIDAS)
(Freeborough et al., 1997). Two methods for quantifying
rates of global gray matter atrophy and 2 methods for
quantifying rates of whole brain atrophy were subsequently
applied over 6- and 12-month intervals as follows.
2.2.1. Segmentation and subtraction of serial GM
volumes
All images and brain regions were transformed into
Montreal Neurological Institute 305 atlas space following a
12-degrees of freedom registration, but applying only 6 dof
(translations and rotations), and images were resampled to
produce isotropic voxels (1  1  1 mm3). Baseline and
repeat images in Montreal Neurological Institute 305 space
were segmented into GM, WM, and cerebrospinal fluid
using SPM5 (http://www.fil.ion.ucl.ac.uk/spm/; Wellcome
Trust Centre for Neuroimaging, UCL Institute of Neurol-
ogy, London, UK) (Ashburner and Friston, 2005). The re-
sulting global GM probability maps were transformed into
binary masks (Fig. 1) by applying a threshold which in-
luded voxels that had a probability  0.5 into the final
mage. The volumes of the binary GM masks were deter-
ined and global GM atrophy was quantified as (baseline
M volume) - (repeat GM volume).
.2.2. Nonlinear registration and Jacobian integration
ver GM
The 6- and 12-month repeat images in standard atlas
pace were registered to baseline using a 12-dof affine
egistration (Woods et al., 1998), and the intensity of the
baseline and repeat images were normalized to each other.
The baseline brain region, morphologically dilated 3 times,
was used to crop baseline and registered repeat images.
Using the result of the affine registration, a nonlinear fluid
registration was applied to warp the cropped repeat image to
the cropped baseline image (Freeborough and Fox, 1998).
The fluid algorithm iteratively drove the deformation
field to maximize the cost function (cross correlation) of
the voxels while forcing the deformation field to satisfy the
compressible viscous fluid model. At each iteration, the
body force for the fluid equation was calculated as the
derivative of the cost function. Exit criteria were satisfied
when the mean body force fell below a threshold of 5.0 
108 (a value based on optimization of the determinant of
he Jacobian matrix in a subset of 6 controls and 6 patients
n whom we ran the nonlinear registration for 1500 itera-
ions), and windowed sinc interpolation was used to gener-
te the final registered repeat image. All fluid registrations
ere visually inspected to ensure there was adequate match-
ng of the baseline and fluidly-registered repeat images. The
esulting deformation field allowed the Jacobian matrix for
ach voxel to be obtained. The determinant of these matri-
oM
s
b
i
m
e
e
m
p
c
2
(
p
A
“
w
u
o
d
D
c
f
w
a
a
c
t
w
G
tter stru
1196 V.M. Anderson et al. / Neurobiology of Aging 33 (2012) 1194–1202ces describes the expansion (1) and contraction (1) at
each voxel. GM regions of interest were generated from the
SPM5 binary baseline GM images, and global GM atrophy
was quantified by integrating the Jacobian values of expan-
sion and contraction within these regions.
2.2.3. Brain boundary shift integral
The original 6- and 12-month repeat images in standard
atlas space were registered to baseline using a 12-dof affine
registration (Woods et al., 1998). The repeat brain region
and image were resliced using the transformation parame-
ters obtained. The intensity of the baseline and repeat im-
ages were normalized to each other by performing a linear
regression of the intensity of cerebrospinal fluid, GM, WM,
and the brain between the baseline and repeat images
(Leung et al., 2010). From each registered image pair the
brain volume change was calculated by integrating the sam-
pled difference of brain voxel intensities over a region
defined as the intersection of the baseline and repeat brain
regions dilated by 1 voxel minus the intersection of the
baseline and repeat region eroded by 1 voxel (Freeborough
and Fox, 1997). The intensity window was automatically
determined by the intensity of CSF and GM in the baseline
and repeat images (Leung et al., 2010).
2.2.4. SIENA
Percentage brain volume change between the 6- and
12-month time points and baseline was estimated with
SIENA (Smith et al., 2001, 2002). The brain regions
btained from the initial segmentation of images using
IDAS were utilized, but SIENA was used extract a
kull image from all scans (Smith, 2002). Baseline and
repeat brain images were then aligned to each other using
Fig. 1. Example binary gray matter segmentation provided by SPM5 (htt
Institute of Neurology, London, UK), which includes subcortical gray mathe skull images to constrain the registration scaling c(Jenkinson and Smith, 2001; Jenkinson et al., 2002), and
oth baseline and repeat brain images were resampled
nto the space halfway between the 2. Tissue-type seg-
entation was carried out in order to find brain/nonbrain
dge points (Zhang et al., 2001), and then perpendicular
dge displacement between the 2 time points was esti-
ated at these edge points. Finally, the mean edge dis-
lacement was converted into a global estimate of per-
entage brain volume change between the 2 time points.
.3. Statistical analysis
Statistical analyses were performed using STATA 11
StataCorp, College Station, TX, USA). Atrophy was ex-
ressed as a percentage of baseline volume and annualized.
trophy rates are expressed as a positive number (and
growth” expressed as a negative number). Comparisons
ithin subject groups between GM atrophy rates estimated
sing the 2 techniques were made by calculating the mean
f the paired differences, and by calculating a 95% confi-
ence interval (CI) assuming normality of these differences.
ifferences in the variances of GM atrophy rates were
ompared by reporting the ratio of the SDs, with 95% CIs
ound using Pitman’s method. Linear regression analyses
ere used to compare GM atrophy rates between the control
nd patient groups using a group indicator and adjusting for
ge and gender as covariates.
Sample size calculations were performed for a trial in-
luding baseline and 1 follow-up MRI, and were based on
he standard formula (Fox et al., 2000; Kirkwood, 1988),
ith 90% power to detect a 20% reduction in either global
M or whole brain atrophy rate at the 5% 2-tailed signifi-
w.fil.ion.ucl.ac.uk/spm/; Wellcome Trust Centre for Neuroimaging, UCL
ctures.p://wwance level.
a1197V.M. Anderson et al. / Neurobiology of Aging 33 (2012) 1194–1202Sample size per trial armuv222/1-22
u  1.28 to provide 90% power; v  1.96 to test at the 5%
significance level. 1 and 2 are the mean GM or brain
trophy rates in the placebo and treatment groups. 2 is the
variance of the GM or brain atrophy rate (the variance in the
patient group).
Calculations were performed both without taking normal
aging into account (assuming a completely effective treat-
ment would reduce the atrophy rate to 0), and allowing for
normal aging (assuming a completely effective treatment
would reduce the atrophy rate to the rate observed in con-
trols). The mean rate in the treatment group was taken as a
percentage of the difference between the control atrophy
rate (or 0 when not taking aging into account) and the
atrophy rate in patients with AD. An immediate and con-
stant treatment effect was assumed. The effect of the atro-
phy measurement technique on sample sizes was assessed
by determining the ratios of sample sizes, with 95% bias-
corrected and accelerated bootstrap CIs calculated (10,000
bootstrap samples) to indicate the precision with which the
ratios had been estimated.
3. Results
The AD and control subjects were well matched for age
(AD mean 69.6 years [SD 7.2], control mean 69.3 years [SD
Table 1
Mean (SD) annualized gray matter and brain atrophy rates
Mean (SD) atrophy (%
Controls (n  19)
6 months
Gray matter atrophy
Segmentation and subtraction
All subjects 0.86 (4.24)
Excluding outliers (1 control, 1 AD) 0.01 (1.97)
Jacobian integration 0.42 (0.47)
Whole brain atrophy
BBSI 0.51 (0.57)
SIENA 0.34 (0.89)
1 year
Gray matter atrophy
Segmentation and subtraction
All subjects 0.92 (2.21)
Excluding outliers (1 control, 1 AD) 0.49 (1.19)
Jacobian integration 0.46 (0.27)
Whole brain atrophy
BBSI 0.64 (0.44)
SIENA 0.67 (0.82)
Mean (SD) global gray matter atrophy rates (% per year) in patients with
SPM5 segmentation and subtraction of GM volumes, and (2) nonlinear reg
brain atrophy rates quantified using the BBSI and SIENA. Estimated sampl
trial to provide 90% power to detect a 20% reduction in atrophy at the 5%
sizes can be extrapolated from the results given by multiplying by the squ
in the table would be multiplied by 4/5 squared, or 16/25. For sample siz
Key: AD, Alzheimer’s disease; BBSI, brain boundary shift integral; CI, c
normalization, of atrophy.7.1]), while there was a smaller proportion of males in theAD group compared with controls (AD 14 males:23 fe-
males; controls 10 males:9 females).
Annualized GM and whole brain atrophy rates for pa-
tients with AD and control subjects using the different
techniques are reported in Table 1. Fig. 2 shows the annu-
ear) Sample size (95% CI)
(n  37) Not allowing for aging Allowing for aging
0 (2.66) 771 (376–2322) 2081 (413 to  10000)
1 (2.60) 666 (336–1941) 661 (255–3284)
7 (1.37) 314 (162–953) 540 (243–2252)
7 (1.26) 296 (156–668) 617 (257–2184)
3 (1.63) 337 (178–871) 485 (216–1685)
7 (2.86) 763 (158 to  10,000) 2047 (262 to  10,000)
6 (1.64) 184 (125–282) 273 (151–617)
1 (0.96) 120 (75–221) 202 (119–420)
9 (0.91) 110 (75–167) 240 (142–469)
2 (1.25) 111 (70–178) 196 (110–425)
d control subjects calculated over intervals of 6 and 12 months using: (1)
n and Jacobian integration over GM regions. Also included are the global
(95% CIs) for each method are also given for a placebo-controlled clinical
cance level, either with or without allowing for aging. Alternative effect
he ratio of the effect sizes, e.g., for a 25% effect size, the estimates given
d on 80% power, estimates should be multiplied by 0.747.
ce interval; GM, gray matter; SIENA, structural image evaluation, using
6m 12m 6m 12m
)73=n(DA)91=n(slortnoC
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Fig. 2. Gray matter (GM) atrophy rates in Alzheimer’s disease (AD) and
control subjects. Gray matter atrophy rates (% per year) in patients with
Alzheimer’s disease and control subjects calculated over intervals of 6 and
12 months using: (1) SPM5 segmentation and subtraction of GM volumes,
and (2) nonlinear registration and Jacobian integration over GM regions.
Arrows indicate the measurements from 2 subjects (1 control, 1 AD) for
whom the segmentation and subtraction estimates of atrophy are markedlyper y
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suggests that SPM5 segmentation and subtraction produced
larger than expected GM volume changes in 1 control sub-
ject (rate of GM atrophy 16.5% per year using the 6-month
scan and 8.7% per year using the 12-month scan), and 1
patient with AD (rate of GM atrophy 11.6% per year
using the 12-month scan). The images and GM segmenta-
tions of these subjects showed no apparent problems on
visual inspection. To examine their influence on the results
for segmentation and subtraction, we present results of the
analyses both including and excluding them.
Mean annualized GM atrophy rates were similar at both 6
and 12 months. In controls and patients, Jacobian integration
gave lower mean atrophy rates than segmentation and subtrac-
tion (when including the 2 outliers) over both 6-month and
12-month intervals, although none of the differences were
statistically significant. The SD of the annual rates found by
Jacobian integration in controls was 0.12 (95% CI, 0.08–0.20,
p 0.001) that of the SD of the segmentation and subtraction
rates. In the AD group the corresponding ratio of SDs was 0.34
(95% CI, 0.25–0.46, p  0.001).
Mean baseline GM volume was 653 mL (SD 53) in
controls, and 540 mL (SD 69) in patients with AD (mean
difference adjusted for age and gender was 108 mL, 95%
CI, 74–142, p  0.001). The mean differences in GM
trophy rates between patients and controls were similar
hen calculated over 6- or 12-month intervals using each
echnique; mean patient-control difference (adjusted for age
nd gender) measured over the 12-month interscan interval
as 1.44% per year (95% CI, -0.10 to 2.98, p  0.067)
using segmentation and subtraction and 1.54% per year
(95% CI, 1.08–2.00, p  0.001) using Jacobian integration.
A greater difference in GM atrophy rates between patients
and controls was observed with segmentation and subtrac-
tion when excluding the 2 subjects with large volume
changes (mean difference over the 12-month interval was
2.21% per year, 95% CI, 1.32–3.11, p  0.001).
Table 1 also shows the estimated sample size require-
ments for trials with 90% statistical power to detect a 20%
reduction in GM or whole brain atrophy rate, either with or
without allowing for aging. The estimated sample sizes
were smaller when using Jacobian integration to quantify
GM atrophy compared with segmentation and subtraction:
for a 6-month trial the estimated sample size using Jacobian
integration (allowing for aging) was 0.26 (95% CI, 0.01–
1.20) that of the sample size using segmentation and sub-
traction, although this was not statistically significant. For a
12-month trial the corresponding ratio was 0.10 (95% CI,
0.01–0.72) which was statistically significant. The sample
size estimates for segmentation and subtraction for a 12-
month trial were influenced to a large extent by the 2
subjects with large volume changes quantified using seg-
mentation and subtraction — excluding these subjects re-
duced the sample size estimates to levels similar (but still
larger) than those for Jacobian integration. Estimated sam-ple sizes were similar for global GM atrophy rate measured
using Jacobian integration to whole brain atrophy rate mea-
sured by either the BBSI or SIENA.
4. Discussion
In this study we assessed global GM atrophy rates from
serial MRI over 6- and 12-month intervals in probable AD
and control subjects, using 2 different measurement tech-
niques. First we used the standard approach of measuring
GM volumes on each scan separately (using SPM5) and
then calculated the atrophy by subtracting the second value
from the first. Second, we used a “direct” measure derived
from nonlinear registration of each pair of scans and then
integration of the Jacobian values over the global GM re-
gion. We compared these measurements both to each other
and to 2 whole brain atrophy measures that are currently
utilized in clinical trials in AD, namely the BBSI and SI-
ENA. We found evidence that GM atrophy is greater in
patients with AD compared with controls (4 times greater)
over intervals as short as 6 months. Furthermore, we have
demonstrated that Jacobian integration reduces variability
and may offer increased statistical power compared with
segmentation and subtraction of serial GM volumes, and
that it offers similar statistical power to whole brain atrophy
rates measured by the BBSI and SIENA. In addition, Jaco-
bian integration may be a more robust technique for mea-
suring GM atrophy than SPM5 segmentation and subtrac-
tion which produced what appeared to be unexplained and
erroneous results in 2 subjects.
Widespread involvement of the GM (cortical and deep
GM) in AD has been shown using statistical mapping tech-
niques and specific region-of-interest analyses on MRI (de
Jong et al., 2008; Serra et al., 2009; Singh et al., 2006).
However, it has been demonstrated that atrophy rates within
the cortex are not uniform either spatially or temporally in
patients with mild cognitive impairment (MCI) and AD
(McDonald et al., 2009; Thompson et al., 2003; Whitwell et
al., 2007). It has been suggested that analyzing larger re-
gions of the brain may be more powerful (because of pre-
cision issues) than using small regions (Hua et al., 2008a),
and our study investigated global GM atrophy as a marker
of disease progression, which may be influenced less by
disease stage or severity than more localized cortical region-
of-interest measures.
Using 2 different techniques for measuring global GM
atrophy, we demonstrated a substantial loss of GM in pa-
tients with AD over an interval as short as 6 months, and the
annual atrophy rate provided by segmentation and subtrac-
tion was similar to that derived using similar methodology
for the cortex in a previous study of patients with dementia
(2.4% per year [SD 2.9] vs. 2.8% per year [SD 1.8]) (Carde-
nas et al., 2003). The mean GM atrophy rate provided by
Jacobian integration was lower than that provided by seg-
mentation and subtraction in our study. The Jacobian inte-
1199V.M. Anderson et al. / Neurobiology of Aging 33 (2012) 1194–1202gration technique used in this study has been applied pre-
viously to determine the rate of hippocampal atrophy in
patients with AD. Similarly to our study, lower atrophy
rates were obtained using Jacobian integration compared
with segmentation and subtraction of serial hippocampal
volumes (Barnes et al., 2007, 2008). Underestimation of
global brain atrophy was also found when applying this
Jacobian integration technique to MRI on which atrophy has
been simulated (Camara et al., 2008). One reason that may
underlie this finding could be the inclusion of partial volume
and CSF voxels in the region of interest, in our case the
baseline GM. These voxels may increase in volume over
time as the brain atrophies, partially negating any real GM
loss that has occurred. In addition, small inaccuracies in the
registration of images or interpolation could account for
errors in the calculation of the deformation field.
Nonlinear registration and Jacobian integration has been
utilized previously in patients with MCI and AD in both
cross-sectional and longitudinal studies (also called tensor-
based morphometry) (Hua et al., 2008a, 2008b; Leow et al.,
2009; Studholme et al., 2004). These studies have used the
calculated deformations to examine the distribution of atro-
phy at a group level, and when atrophy has been quantified,
it has been limited to smaller regions-of-interest defined on
template images, rather than global scan-specific segmenta-
tions. Moreover, these studies have not investigated the
ability of these techniques to measure atrophy relative to
other manual or automated measures. However, 1 study
investigating tissue growth in the WM and GM of infants
reported a general agreement between estimates provided
by a nonlinear registration and Jacobian integration tech-
nique and those provided by segmentation and subtraction
of volumes (Aljabar et al., 2008). The discrepancy with the
results of the comparison in our study may be explained by
the fact that growth rather than atrophy was being quanti-
fied, and also that different nonlinear registration and seg-
mentation algorithms were being used (free-form deforma-
tion and expectation maximization respectively).
The mean rates of atrophy provided by Jacobian integra-
tion were lower than those from segmentation and subtrac-
tion (although not statistically significantly), but there was
evidence that variance was reduced using this technique,
presumably due to reduced measurement error. It must also
be noted that segmentation and subtraction produced 1 or 2
extreme outliers (Fig. 2), which were neither plausible nor
consistent over time. While it may have been possible to
optimize the images or segmentation process in these 2
subjects to rectify any problems which may have led to
these results, 1 of the advantages of the Jacobian (registra-
tion-based) method seems to be a reduction in the potential
for large errors in measurement of change. This may be
advantageous in clinical trials where minimizing the need
for intervention in the case of erroneous results is beneficial
when processing hundreds of images. Power calculations
estimating patient numbers for therapeutic trials dependboth on the difference in means between treatment arms and
the variance of measured atrophy, and consequently, the
sample size estimates for a placebo-controlled trial using
GM atrophy rate as an outcome measure were consistently
smaller using the Jacobian integration technique than seg-
mentation and subtraction. Interestingly, GM Jacobian in-
tegration provided relatively similar statistical power to
whole brain atrophy measures from the BBSI and SIENA
(as previously reported in this patient population, very sim-
ilar results were seen using either the BBSI or SIENA;
Smith et al., 2007). However GM atrophy may be more
disease-specific and clinically relevant than whole brain
atrophy or ventricular enlargement, given the density of
neuronal cell bodies in the GM and the associations that
have been shown between GM atrophy and cognition (de
Jong et al., 2008; Mouton et al., 1998). It may well be that
the GM-focused measures might have particular advantages
in early disease. For example GM atrophy, but not WM
atrophy, has been observed in people with amnestic MCI
(Balthazar et al., 2009), while evidence of a sequential
relationship between hippocampal atrophy and WM pathol-
ogy in early AD has been reported (Villain et al., 2010).
However, the postulated gain in using our proposed GM
atrophy rate measurement method compared with methods
measuring whole brain atrophy rates in MCI and early AD
requires further investigation.
It should be noted that in addition to sample size esti-
mates taking normal aging into account, we provided esti-
mates without taking normal aging into account, to enable
comparisons with previously published data using similar
nonlinear registration and Jacobian integration techniques.
A study based on atrophy rates in the temporal lobe pro-
vided by tensor-based morphometry reported sample size
estimates ranging from 70 to 104 subjects per treatment
arm, depending on the parameters used for nonlinear regis-
tration, for a 25% reduction in atrophy rate and 90% power
(Hua et al., 2009). It is possible to extrapolate the sample
sizes estimated in our study to other effect sizes by multi-
plying by the square of the ratio of the effect sizes. There-
fore, using the Jacobian integration methodology, an esti-
mated 77 patients per treatment arm would be required to
detect a 25% reduction in GM atrophy rate in our study (120
subjects multiplied by 16/25; i.e., 4/5 squared). These sam-
ple sizes compare well with those derived using similar
methods over the temporal lobe in Hua et al. (2009). How-
ever, it is important to take normal aging into account, or the
potential for a therapeutic effect may be overestimated
(Schott et al., 2010); in this instance, 130 subjects per
treatment arm would be required for a 25% effect size and
90% power when taking normal aging into account.
Although this study has shown that global GM atrophy
could be used to track disease progression in patients with
AD, 1 limitation of the study was that we did not look at the
association of GM atrophy with clinical outcomes, which
could have strengthened the evidence for our hypothesis
1200 V.M. Anderson et al. / Neurobiology of Aging 33 (2012) 1194–1202that GM atrophy may be more disease-specific and clini-
cally relevant than measures of whole brain atrophy or
ventricular enlargement in patients with AD. Furthermore,
this was a preliminary study, and additional validation and
optimization of the nonlinear registration and Jacobian in-
tegration technique should be performed. Although we used
a 0.5 probability of being GM for classification of the
baseline GM mask, other probability thresholds should be
investigated, as misclassified or partial volume voxels will
increase measurement error. This study used SPM5 to clas-
sify the different tissues, but SPM8 is now available which
includes new segmentation methodology that may offer a
more accurate segmentation of the convoluted cortex. This
may have offered improved results in the 2 subjects who
gave results which were inconsistent with what we ex-
pected. Additionally, it should be investigated whether ero-
sion of the resulting GM masks could improve the sensitiv-
ity and precision of atrophy measurement. As mentioned
previously, other nonlinear registration algorithms are avail-
able and could also be investigated (Christensen et al., 1996;
Rueckert et al., 1999; Shen and Davatzikos, 2003), as it has
been shown that nonlinear registration algorithms can differ
in their accuracy and reproducibility (Klein et al., 2009;
Yanovsky et al., 2009). Similarly, techniques which attempt
to compute temporally consistent segmentations for longi-
tudinal atrophy assessment by jointly segmenting serial vol-
umes have been proposed, and the relative merits of these
methods should be compared with that presented in the
current study (Xue et al., 2006; Wolz et al., 2010). It has
also been shown that the reliability of nonlinear registration
and quantification of deformations can be affected by the
pulse sequence, coil-type and postprocessing, and these
factors, and the parameters of the nonlinear registration,
should be optimized in any future prospective studies uti-
lizing these techniques (Leow et al., 2006). Additionally,
future work should investigate the application to patients
with MCI and neurological disorders other than AD, such as
multiple sclerosis, in which there is currently considerable
interest in GM pathology.
We conclude that nonlinear registration and integration
of Jacobian values has the potential to track GM atrophy in
patients with AD from serial MRI, and provide similar
statistical power to currently used registration-based whole-
brain atrophy measures, and increased statistical power
compared with segmentation and subtraction of serial GM
volumes. These results may have implications for future
clinical trials of disease-modifying treatments in AD.
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